Sponsored

Imugene (ASX: IMU) licences allogeneic cell therapy from US-based Precision Biosciences

August 16, 2023 07:30 AM IST | By Sonal Goyal
 Imugene (ASX: IMU) licences allogeneic cell therapy from US-based Precision Biosciences
Image source: Company website

Highlights

  • Imugene is acquiring a license to azer-cel allogeneic CD19 CAR T cell therapy program.
  • Azer-cel has the potential to become the first approved allo CAR T cell therapy for cancer.
  • onCARlytics program and azer-cel complement each other.
  • Imugene to lease a GMP manufacturing facility to complete clinical trials.

Imugene Limited (ASX: IMU) has inked an agreement with Precision Biosciences, Inc., based in North Carolina in the US, for an exclusive licence to the latter’s azer-cel (azercabtagene zapreleucel) allogeneic CD19 CAR T cell therapy program.

Azer-cell reported encouraging results in the ongoing multi-centre Phase 1b clinical trial (patients with non-Hodgkin’s lymphoma (NHL) and acute B-cell lymphoblastic leukaemia (B-ALL)). The results indicated clinically meaningful activity with an acceptable safety profile. Also, it was found that the therapy was especially strong in DLBCL (Diffuse Large B Cell Lymphoma) patients who relapsed after CAR T therapy.

The company also highlighted that azer-cel complements its onCARlytics platform.

IMU believes that there is the potential to begin a registrational study in 2024 in patients with 3rd and 4th line DLBCL. With this development, azer-cel is expected to become the first FDA-approved allogeneic CAR T therapy for blood cancers.

Azer-cel demonstrated significant results across different trials

Currently, the therapy is under a multi-centre Phase 1b clinical trial. As discussed above, in this trial, azer-cel delivered substantial results, especially in DLBCL patients who had relapsed after auto CAR T therapy.

The data set indicated an overall response rate of 83%, a complete response rate of 61%, with 55% durable response more than or equal to six months in this auto CAR T relapse setting.

The update suggested that 60-70% of patients treated with auto CD19 CAR T cell therapy such as Kymriah®, Yescarta® or Breyanzi® will have cancer recurrence or progression.

Azer-cel reported a positive response rate along with an acceptable safety profile in the broader group of patients with relapsed NHL.

Azer-cel also indicated positive results in DLBCL patients who relapsed after CAR T, and the response rate with molecular remissions in this setting was positive. IMU said that considering this dataset, azer-cel can improve outcomes in the growing and large population with unmet needs.

Data source: Company update

In June 2023, a meeting was held with the FDA to get guidance for entering a phase 2 registration study. IMU said that the intended commercial azer-cel product will be evaluated in the clinic and will be used in the potential registrational clinical trial.

Consideration for acquiring right from Precision

As per the licence agreement, Imugene has agreed to pay Precision Biosciences-

Data source: Company update

The company will fund the transaction through existing cash reserves and can partially pay through its equity if it elects to do so. Moreover, IMU will pay US$3 million as an introduction fee to Chimeric Therapeutics Limited in relation to the acquisition.

Advancing Phase 1b clinical trial

Imugene will lease a state-of-the-art 32,800 sq feet GMP manufacturing facility in North Carolina to finalise a phase 1b and phase 2 registrational clinical trial.  

IMU’s shares last traded at AU$0.094 apiece on 15 August 2023 with a market cap of AU$603.76 million.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

Recent Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.